Silence Therapeutics (NASDAQ:SLN) Receives Buy Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research report sent to investors on Friday,Benzinga reports. They currently have a $75.00 price target on the stock.

A number of other equities analysts have also recently issued reports on SLN. Chardan Capital reiterated a “buy” rating and set a $55.00 target price on shares of Silence Therapeutics in a report on Thursday. Jefferies Financial Group assumed coverage on Silence Therapeutics in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $40.00 target price on the stock. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $49.00 price target on shares of Silence Therapeutics in a research note on Tuesday, October 8th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $57.20.

Silence Therapeutics Price Performance

Shares of NASDAQ SLN traded down $1.28 during mid-day trading on Friday, hitting $12.70. The company’s stock had a trading volume of 438,712 shares, compared to its average volume of 202,369. The stock has a market cap of $380.09 million, a price-to-earnings ratio of -8.09 and a beta of 1.30. The company’s fifty day simple moving average is $17.98 and its 200-day simple moving average is $19.16. Silence Therapeutics has a one year low of $8.94 and a one year high of $27.72.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings data on Thursday, August 15th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.10). The company had revenue of $0.76 million for the quarter, compared to the consensus estimate of $11.28 million. Silence Therapeutics had a negative return on equity of 58.28% and a negative net margin of 222.44%. On average, sell-side analysts predict that Silence Therapeutics will post -1.55 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SLN. Lombard Odier Asset Management USA Corp boosted its holdings in shares of Silence Therapeutics by 0.7% in the 2nd quarter. Lombard Odier Asset Management USA Corp now owns 2,405,998 shares of the company’s stock valued at $45,714,000 after buying an additional 17,086 shares during the last quarter. Redmile Group LLC acquired a new position in shares of Silence Therapeutics during the 1st quarter worth about $43,798,000. Janus Henderson Group PLC raised its holdings in shares of Silence Therapeutics by 32.8% in the 3rd quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock valued at $19,798,000 after purchasing an additional 268,250 shares during the period. Millennium Management LLC lifted its stake in Silence Therapeutics by 91.2% in the 2nd quarter. Millennium Management LLC now owns 782,941 shares of the company’s stock valued at $14,876,000 after purchasing an additional 373,523 shares during the last quarter. Finally, Eventide Asset Management LLC bought a new stake in Silence Therapeutics in the third quarter valued at approximately $11,635,000. 98.73% of the stock is currently owned by institutional investors.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.